Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Verily Life Sciences LLC

Latest From Verily Life Sciences LLC

Future Value Creation Depends On Incorporating Data-Driven Technology, EY Concludes

Biopharmas and other life sciences firms risk getting left behind by technology firms if they don't begin addressing patient needs more directly through data-driven technological advances, such as those to aid clinical development or treatment decisions with real-time patient data.

Digital Health Business Strategies

New Report Spotlights Intensifying Rivalry Between Tech And Health-Care Companies

More than 75% of Fortune 500 life-science companies may fall out of that ranking by 2023 amid rising competition from tech giants like Apple, Microsoft and Alphabet, as well as smaller tech players that offer data-driven health services and products that meet the needs of a changing value-based and consumer-driven health-care environment, according to a new Ernst & Young report.

Digital Health Commercial

Device/Diagnostics Quarterly Deal-Making Statistics, Q4 2017

Device fundraising during the fourth quarter totaled $2.6 billion, making it the strongest quarter of the year. Q4 M&A activity reached $3.9 billion, higher than Q3's $3.4 billion, but still one of the lowest quarters of the year. Both fourth quarter diagnostics financings and M&As hit an all-year low of $622 million, and $2.8 million, respectively.

Deals Market Intelligence

Market Intel: Bioelectronics, Imaging Fortify Medtech's Defense Against Rheumatoid Arthritis

As rheumatoid arthritis treatment improves in the biologics era, patients need fewer joint replacements. Instead, they now require more closely monitored, agile care, in the face of a growing shortage of qualified rheumatologists. These demands help propel digital health applications, bioelectronic devices and novel imaging modalities into the medtech spotlight.

Inflammation Neurology
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Nanotechnology, Chips, etc.
  • In Vitro Diagnostics
    • Biosensors
    • Glucose Testing
  • Medical Devices
    • Implantable Devices
    • Monitoring Equipment & Devices
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Metabolic Disorders
  • Ophthalmic
  • Alias(es)
  • Google Life Sciences
  • Google life sciences spin-off
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Verily Life Sciences LLC
  • Senior Management
  • Andy Conrad, CEO
    Jessica Mega, MD, CMO
    Vikram Bajaj, PhD, CSO
    Brian Otis, PhD, CTO
    Linus Upson, Head, Engineering
    Tom Stanus, Head, Software
  • Contact Info
  • Verily Life Sciences LLC